Daphne Quimi Receives Stock Award at Amicus Therapeutics Inc (FOLD) — SEC Form 4, Jan 04, 2022
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Equity Position
336K sh
294,670 → 335,947
Equity Change
+14.0%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Daphne Quimi CIK 0001543031 |
CFO
|
Daphne Quimi at Amicus Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Amicus Therapeutics Inc
| 2023-01-19 | Sell | -$152,444 | View |
| 2023-01-13 | Award | — | View |
| 2023-01-06 | - | — | View |
| 2023-01-04 | Award | — | View |
| 2022-09-06 | Sell | -$49,621 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2021-12-31 | F - Tax Payment | 10,502 D | $11.55 | -$121,298 | 280,127 | Direct |
| Common Stock | 2022-01-02 | F - Tax Payment | 15,778 D | $11.55 | -$182,236 | 264,349 | Direct |
| Common Stock | 2022-01-03 | F - Tax Payment | 1,538 D | $12.11 | -$18,625 | 262,811 | Direct |
| Common StockF1F2 | 2022-01-03 | A - Award/Grant | 73,136 A | — | 335,947 | Direct | |
| Common Stock | 2022-01-04 | F - Tax Payment | 4,041 D | $12.48 | -$50,432 | 331,906 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $12.11 | 2022-01-03 | A - Award/Grant | 134,044 A | $0.00 | 2032-01-03 | 134,044 Common Stock | Direct |
Footnotes (3)
- F1
- Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. Show more
- F2
- The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023. Show more
- F3
- These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Show more
Related filings at Amicus Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
2
institutional managers reporting a position
Largest by reported value
- Ifp Advisors, Inc $11.5K
- Huntington National Bank $14
5%+ Holders · 13D/G
5 filers
-
Barclays Plc 5.7%
-
Ubs Group Ag 5.5%
-
Glazer Capital, Llc 0.0%
-
Black Rock, Inc. 7.4%
Other insiders at Amicus Therapeutics Inc
GET /v1/forms/4/0001209191-22-001205
API docs
View Original SEC Filing